2025-05-29-Jefferies-美国_生物技术_邀请最惠国操作-网络直播_6月3日_美国东部时间上午11点_6页_89kb
报告摘要
- This is a biotechnology equity research report from Jefferies LLC, dated May 29, 2025, authored by Akash Tewari and other analysts.
- A webcast invitation is sent for June 3, 2025, at 11 AM EDT, focusing on regulatory challenges in the healthcare sector, specifically addressing "Operation MFN," which highlights the "Most Favored Nation (MFN)" policy as one of three major regulatory overhangs alongside FDA disruption and tariffs. The webcast covers scenarios like legislation, CMMI, and IRA, along with mitigation steps.
- Jefferies provides proprietary Excel data detailing the top 50 Medicare Part D/B drugs and price spreads between U.S. and ex-U.S. markets, as well as a separate deep dive on tariffs.
- The report includes analyst certifications, personnel details, ratings (Buy, Hold, Underperform), valuation methodologies, and extensive disclaimer information for the investment research, emphasizing conflicts of interest and legal disclaimers required for various jurisdictions.
- Key regulatory overhangs discussed include MFN, FDA disruption, and tariffs, impacting the healthcare sector's investment strategies. The summary underscores the need for analysis-backed mitigation steps in these areas.
展开完整摘要
试读结束，高清完整版pdf/doc/ppt,请点下载
